Max Planck Society

Ancient nomads you’ve probably never heard of disappeared from Europe 1,000 years ago. Now, DNA analysis reveals how they lived

Retrieved on: 
星期四, 四月 25, 2024

For centuries, our main sources of information have been pottery sherds, burial sites and ancient texts.

Key Points: 
  • For centuries, our main sources of information have been pottery sherds, burial sites and ancient texts.
  • But the study of ancient DNA is changing what we know about the human past, and what we can know.

Who were the Avars?


The Avars were a nomadic people originating from eastern central Asia. From the 6th to the 9th century CE, they wielded power over much of eastern central Europe.

  • The Avars are renowned among archaeologists for their distinctive belt garnitures, but their broader legacy has been overshadowed by predecessors such as the Huns.
  • Nevertheless, Avar burial sites provide invaluable insights into their customs and way of life.

Kinship patterns, social practices and population dynamics

  • We combined ancient DNA data with archaeological, anthropological and historical context.
  • As a result, we have been able to reconstruct extensive pedigrees, shedding light on kinship patterns, social practices and population dynamics of this enigmatic period.


We sampled all available human remains from four fully excavated Avar-era cemeteries, including those at Rákóczifalva and Hajdúnánás in what is now Hungary. This resulted in a meticulous analysis of 424 individuals. Around 300 of these individuals had close relatives buried in the same cemetery. This allowed us to reconstruct multiple extensive pedigrees spanning up to nine generations and 250 years.

Communities were organised around main fathers’ lines

  • Our results suggest Avar society ran on a strict system of descent through the father’s line (patrilineal descent).
  • In contrast, women played a crucial role in fostering social ties by marrying outside their family’s community.
  • Our study also revealed a transition in the main line of descent within Rákóczifalva, when one pedigree took over from another.
  • Our results show an apparent genetic continuity can mask the replacement of entire communities.

Future direction of research


Our study, carried out with researchers from the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany and at Eötvös Loránd University in Budapest, Hungary, is part of a larger project called HistoGenes funded by the European Research Council. This project shows we can use ancient DNA to examine entire communities, rather than just individuals. We think there is a lot more we can learn.

  • Now we aim to deepen our understanding of ancestral Avar society by expanding our research over a wider geographical area within the Avar realm.
  • Additionally, we plan to study evidence of pathogens and disease among the individuals in this research, to understand more about their health and lives.
  • Another avenue of research is improving the dating of Avar sites.
  • Bunbury receives funding from the Australian Research Council (ARC) (project number CE170100015).
  • Guido Alberto Gnecchi-Ruscone receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 856453.

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Retrieved on: 
星期一, 四月 8, 2024

Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system.

Key Points: 
  • Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system.
  • Ayana COO Yanir Aldouby, commented, "After an extensive search, we are pleased to have selected Scinai Bioservices as our CDMO for our future projects.
  • We were particularly attracted to the team's experience in bio-pharmaceutical drug development and manufacturing for clinical trials while meeting stringent international regulatory requirements.
  • As Scinai is also in the business of biological drug development, we believe they understand our needs as a small biopharma company.

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Retrieved on: 
星期三, 三月 13, 2024

“We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.

Key Points: 
  • “We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.
  • Dr. Rommel currently serves as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals, Inc.
  • He joined Bayer from Roche, where he was most recently Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED).
  • He has authored more than 70 publications, including papers in Science and Nature, and is an inventor or co-inventor of 18 patents.

EQS-News: World's largest radio telescope – Listen to the universe

Retrieved on: 
星期三, 三月 13, 2024

Extraordinary: The radio dishes are gradually being integrated into the SKA Square Kilometre Array, an international project to build the world's largest radio telescope with sites in southern Africa and in Australia.

Key Points: 
  • Extraordinary: The radio dishes are gradually being integrated into the SKA Square Kilometre Array, an international project to build the world's largest radio telescope with sites in southern Africa and in Australia.
  • This is an achievement of partners from science and industry, nationally and internationally.
  • We now have our focus on series production," says Fabrice Scheid, Managing Director of OHB Digital Connect's Mainz site.
  • The individual segments of the radio dishes are delivered to Cape Town by ship, transported to the desert with heavy equipment and assembled on site.

What’s with the Extra Day? A College of Charleston Professor Explains Lear Year.

Retrieved on: 
星期二, 二月 27, 2024

Our calendar year is based on the time it takes the Earth to complete one full orbit around the Sun.

Key Points: 
  • Our calendar year is based on the time it takes the Earth to complete one full orbit around the Sun.
  • So, in a non-leap year, after 365 days, the Earth would be slightly behind where it started relative to the Sun.
  • The Julian calendar added an extra day at the end of the year every four years.
  • Later on, two extra months were added to the calendar with February being made the last month of the year.

15th International Workshop on Advanced Materials Kicks off in Ras Al Khaimah

Retrieved on: 
星期二, 二月 20, 2024

Today, the 15th International Workshop on Advanced Materials (IWAM) organised by the Ras Al Khaimah Center for Advanced Materials (RAKCAM) kicks off at the Mövenpick Resort on Al Marjan Island.

Key Points: 
  • Today, the 15th International Workshop on Advanced Materials (IWAM) organised by the Ras Al Khaimah Center for Advanced Materials (RAKCAM) kicks off at the Mövenpick Resort on Al Marjan Island.
  • View the full release here: https://www.businesswire.com/news/home/20240219081040/en/
    HH Saud bin Saqr attends the opening of the 15th #IWAMRasAlKhaimah and takes part in a fireside discussion that highlights Ras Al Khaimah’s commitment to scientific progress and innovation.
  • The event is again being held under the patronage of His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, who is participating in a fireside discussion about the importance of advanced materials in solving the world’s greatest challenges.
  • Sir Anthony Cheetham, Chairman of Ras Al Khaimah Center for Advanced Materials, commented: “His Highness Sheikh Saud is dedicated to leveraging education and science as drivers of innovations that contribute to humanity’s advancement - and committed to advancing the field of materials science.

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Retrieved on: 
星期二, 二月 13, 2024

JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales.

Key Points: 
  • JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales.
  • Scinai's broad pharmaceutical development experience, along with its end-to-end biologics drug development and GMP manufacturing facility, drove the Q3 2023 launch of Scinai Bioservices, a boutique end-to-end CDMO business unit, to assist biotech companies efficiently bring their products to market.
  • In addition to expanding the CDMO's business development and sales activities, Halpert will support partnering and out-licensing activities with mid and large cap pharma companies with which Scinai plans on bringing the NanoAbs through clinical trials and towards commercialization.
  • Halpert commented, "I am thrilled to join Scinai where I'll be leading business development and sales of our state-of-the-art end-to-end CDMO services in the global biotech arena.

As the war in Gaza continues, Germany’s unstinting defence of Israel has unleashed a culture war that has just reached Australia

Retrieved on: 
星期二, 二月 13, 2024

His work led him to being offered a stint at Germany’s prestigious Max Planck Institute for Social Anthropology.

Key Points: 
  • His work led him to being offered a stint at Germany’s prestigious Max Planck Institute for Social Anthropology.
  • This came less than two months after the Max Planck Foundation, with war in Gaza raging, had announced “additional funding for German-Israeli collaborations”.
  • What to me is a fair, intellectual critique of Israel, for them is “antisemitism according to the law in Germany”.

A political ideal

  • As he succinctly writes:
    I have a political ideal that I have always struggled for regarding Israel/Palestine.
  • It is the ideal of a multi-religious society made from
    Christians, Muslims and Jews living together on that land.
  • I have a political ideal that I have always struggled for regarding Israel/Palestine.
  • It is the ideal of a multi-religious society made from
    Christians, Muslims and Jews living together on that land.
  • His criticism of current Israeli policy, he insists, stems from the Netanyahu government’s determination to “work against such a goal”.

Self-imposed red lines

  • It is worth pointing out that it is not just happening in Germany.
  • Universities in the United States are under siege from students and community groups variously accusing them of both antisemitism and Islamophobia.
  • Largely, however, what’s happening in Germany is a result of some self-imposed red lines the German press, the German courts and the German parliament have imposed on public debate.
  • Rather, it is a result of Germany’s current belief that its genocidal, antisemitic Nazi past implies future unwavering support for Israel.
  • It might equally be said that Germany has a special responsibility to stridently oppose ethnic cleansing, war crimes and genocide wherever they occur.

Enough?

  • Sharp words from German government officials about the renewed Israeli campaign in Rafah suggest this might be possible.
  • The German Foreign Minister Annalena Baerbock warned recently “the people of Gaza cannot vanish into thin air”.


Matt Fitzpatrick receives funding from the Australian Research Council.

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Retrieved on: 
星期四, 一月 25, 2024

JERUSALEM, Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.

Key Points: 
  • JERUSALEM, Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.
  • Görlich serves as a director of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT).
  • According to MPI-NAT, Görlich has received several other scientific awards including the Heinz Maier-Leibnitz Prize, the EMBO Gold Medal, the Alfried Krupp Prize, the WLA Prize 2022, and the Animal Welfare Research Prize of the German Federal Ministry of Food and Agriculture.
  • Amir Reichman, Scinai's CEO, commented, "On behalf of Scinai's team, I offer sincere congratulations to Dirk on being awarded the 2024 Louis-Jeantet Prize.

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Retrieved on: 
星期二, 一月 16, 2024

Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.

Key Points: 
  • Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.
  • “We are pleased to bring our search for a capable clinical development leader to such a swift, successful resolution and welcome Mark to the team,” said Joern Aldag, Chief Executive Officer at HOOKIPA.
  • “Mark is a tremendous talent with rich experience across the drug development lifecycle.
  • Prior to Evotec, Dr. Winderlich spent more than 12 years in drug development at MorphoSys AG across various roles of increasing responsibility.